Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent developments in tuberculosis vaccines.

Melles Haile1, Gunilla Källenius

  • 1Department of Bacteriology, Swedish Institute for Infectious Disease Control, Solna, Sweden. melles.haile@smi.ki.se

Current Opinion in Infectious Diseases
|May 3, 2005
PubMed
Summary

The Bacille Calmette-Guerin (BCG) vaccine offers limited protection against tuberculosis (TB) in adults, prompting the development of new TB vaccines. Research is ongoing to find more effective immunization strategies for tuberculosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A multi-omics study reveals pathway-level insights and predictive biomarkers in pediatric TB.

Clinical proteomics·2026
Same author

Tuberculosis and HIV Coinfection: Advances and Remaining Concerns.

Cold Spring Harbor perspectives in medicine·2026
Same author

A Multi-Omics Study Reveals Pathway-Level Insights and Predictive Biomarkers in pediatric TB.

medRxiv : the preprint server for health sciences·2026
Same author

A multiplex Mtb-specific FluoroSpot assay measuring IFNγ, IL-2, and TNF-secreting cells can improve accuracy and differentiation across the tuberculosis spectrum.

Journal of clinical microbiology·2025
Same author

Antibody-Fab and -Fc features promote Mycobacterium tuberculosis restriction.

Immunity·2025
Same author

Antibody-Fab and -Fc features promote <i>Mycobacterium tuberculosis</i> restriction.

bioRxiv : the preprint server for biology·2024

Area of Science:

  • Immunology
  • Vaccinology
  • Infectious Diseases

Background:

  • The Bacille Calmette-Guerin (BCG) vaccine is the sole available vaccine against tuberculosis (TB).
  • It is extensively used in the World Health Organization Expanded Programme for Immunization.
  • BCG's efficacy in preventing TB varies significantly across different populations.

Purpose of the Study:

  • To review the benefits and limitations of the BCG vaccine for tuberculosis control.
  • To highlight novel tuberculosis vaccine candidates in clinical trials.

Main Methods:

  • Review of existing research on BCG vaccine efficacy.
  • Identification and summary of new TB vaccine candidates.

Main Results:

Related Experiment Videos

  • BCG vaccine efficacy has shown considerable variability, with a 60-year follow-up study reporting 52% long-term efficacy in American Indians.
  • Reasons for low efficacy may include BCG strain differences, population immunological properties, or environmental mycobacterial exposure.
  • Over 200 new vaccine candidates have been developed, with some currently undergoing clinical trials.

Conclusions:

  • BCG vaccination is widespread but provides waning immunity, offering insufficient protection against TB in adults.
  • New vaccine development is crucial, with over 200 candidates emerging.
  • Clinical trials for new TB vaccines must accommodate diverse populations and immune responses.